SPOTLIGHT -
Dr. Carbone on the Impact of Immunotherapy in Lung Cancer
David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.
Read More
Dr. Carbone on the Importance of Personalizing Immunotherapy in NSCLC
David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.
Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC
David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.
Dr. Carbone Provides Perspective on COVID-19
David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center–James, provides perspective on the novel coronavirus 2019 (COVID-19).
Dr. Carbone on Potential Biomarkers in Lung Cancer
David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.
Dr. Carbone on Immunotherapy Research in Lung Cancer
David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.
Dr. Carbone on Genetic Testing Availability and Accuracy
David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.
Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC